Dicks Sporting Goods Inc vs Novavax Inc — how do they compare? Dicks Sporting Goods Inc trades at $135.72 (market cap $13.26B), while Novavax Inc trades at $12.54 (market cap $1.82B). The key difference: Dicks Sporting Goods Inc is far larger — about 7.3× Novavax Inc's market cap, and Dicks Sporting Goods Inc pays a 3.71% dividend while Novavax Inc pays none. Which is the better fit depends on your goals — on Pluang, investors hold Dicks Sporting Goods Inc for 19 Days and Novavax Inc for 59 Days on average.
| DKS | NVAX | |
|---|---|---|
Market Cap | $13.26B | $1.82B |
Volume | 2,292,035 | 6,198,505 |
Sector | Consumer Cyclical | Health |
52-Week High | $239.17 | $12.56 |
52-Week Low | $121.15 | $6.22 |
Typical Hold Time | 19 Days | 59 Days |
Enterprise Value | $20.31B | $1.39B |
Dividend Yield | 3.71% | — |
Signals from Pluang's Aura AI — not financial advice
DICK'S Sporting Goods (DKS) trades at $134.91, up 2.84% with mixed technical signals showing bearish moving averages but neutral oscillators. The company maintains solid fundamentals with a P/E of 14.86 and ROE of 18.47%, though recent earnings showed a Q2 2026 miss. Analyst consensus remains strongly positive with 56.9% buy ratings and a $153.30 price target, representing 13.6% upside potential from current levels.
While facing securities litigation headwinds, DKS demonstrates operational strength with $1.31B operating cash flow and consistent dividend payments. The stock offers value with attractive valuation metrics, but investors should monitor the ongoing class action lawsuits and potential impact on near-term sentiment despite the fundamentally sound business model.
Novavax (NVAX) trades at $12.41, up 10.61% today, with strong technical momentum and bullish moving average signals. The company shows mixed fundamentals with a low P/E of 3.14 and EV/EBITDA of 1.72, but negative net income margin of -59.87% and negative shareholder equity. Recent earnings beats and FDA approvals for updated COVID-19 vaccines provide near-term catalysts.
Investment outlook remains speculative with significant execution risks despite analyst optimism (74% buy ratings). The company's pivot to Matrix-M adjuvant licensing and partnership model offers growth potential, but negative cash flow and high debt levels pose substantial financial risk. Stock appears undervalued on some metrics but requires careful risk management.
Trailing returns across standard periods
What Pluang investors did over the last 30 days
No sentiment data available yet.
Latest headlines on both assets
Dick's Sporting Goods is a leading omni-channel sporting goods retailer in the US It offers an extensive assortment of authentic sports equipment, apparel, footwear, and accessories through its stores and digital platforms.
Read more on DKS →Novavax, Inc. is a clinical stage biotechnology company. The Company creates novel vaccines to address a broad range of infectious diseases worldwide using proprietary virus-like particle (VLP) technology.
Read more on NVAX →